Logo Image
|Webcasts|October 29, 2020

Implementing Risk-based Monitoring in Oncology Trials Sharing case studies and insights on the impact to study quality and patient safety

Author(s)IQVIA

***Live: Thursday November 12, 2020 at 11am EST***Oncology trials of various types and phases present unique challenges for effectively conducting trials, and firms are implementing risk-based monitoring (RBM) practices to improve quality and patient safety.***On demand available after final airing until Nov. 12, 2021***

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/GSA​

Event Overview: Clinical research & development is at a crossroads, requiring new approaches to deliver drugs to market faster – with less cost – while mitigating risk, and without compromising safety or quality. The market is moving towards risk-based monitoring (RBM) to monitor clinical trials as it provides new levels of efficiency and quality while providing predictability of speed and operational outcomes.

Key Learning Objectives:

  • The industry continues to change, and risk-based monitoring (RBM) is helping pharmaceutical firms improve the efficiency, quality and safety of their oncology trials to bring new therapies to patients faster
  • RBM is using advanced technologies, including AI, ML, and predictive analytics to provide new levels of insights to mitigate risks while improving quality and patient safety
  • Oncology trials are an industry leader in the adoption of RBM practices for their clinical trials – understand why with case studies and lessons learned from this webinar

Speakers: Zabir Macci, Centralized Monitoring Manager, Clinical Operations Process Design,Analytics, IQVIA

Susana Nolley, MPH,mDirector, Clinical Project Management, Oncology Project Leadership, IQVIA

Time and Date: Thursday November 12, 2020 at 11am EST

On demand until Nov. 12 2021.

Sponsor: IQVIA

Register Free: ​ http://www.appliedclinicaltrialsonline.com/act_w/GSA​

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more